	US 12,303,485 B2
	Arsinothricin and methods of treating infections using arsinothricin
Barry Philip Rosen, Coral Gables, FL (US); and Masafumi Yoshinaga, Doral, FL (US)
Assigned to The Florida International University Board of Trustees, Miami, FL (US)
Filed by Barry Philip Rosen, Coral Gables, FL (US); and Masafumi Yoshinaga, Doral, FL (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,267.
Application 17/696,267 is a continuation of application No. 16/163,055, filed on Oct. 17, 2018, granted, now 11,298,335.
Prior Publication US 2022/0202763 A1, Jun. 30, 2022
Int. Cl. A61P 31/04 (2006.01); A61K 31/198 (2006.01); A61K 31/285 (2006.01); A61K 33/36 (2006.01); A61P 31/06 (2006.01); C12N 9/10 (2006.01)

CPC A61K 31/285 (2013.01) [A61P 31/04 (2018.01); C12N 9/1029 (2013.01); C12Y 203/01183 (2013.01)]

13 Claims

1. A method of treating an infection in a subject caused by Mycobacterium tuberculosis that expresses arsinothricin N-acetyltransferase or Mycobacterium bovis that expresses arsinothricin N-acetyltransferase, comprising administering to the subject arsinothricin or a salt thereof and an inhibitor of arsinothricin N-acetyltransferase.